Swiss National Bank grew its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 1.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 294,800 shares of the biopharmaceutical company’s stock after purchasing an additional 3,000 shares during the quarter. Swiss […]
E Fund Management Co. Ltd. raised its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 41.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 13,152 shares of the biopharmaceutical company’s stock after acquiring an additional 3,875 shares during the […]
Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) has been assigned an average rating of “Moderate Buy” from the eleven research firms that are presently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average twelve-month […]
E Fund Management Co. Ltd. boosted its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 41.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 13,152 shares of the biopharmaceutical company’s stock after acquiring an additional 3,875 shares during […]
StockNews.com upgraded shares of Halozyme Therapeutics (NASDAQ:HALO – Free Report) from a hold rating to a buy rating in a research report sent to investors on Tuesday. Other equities analysts also recently issued reports about the stock. The Goldman Sachs Group downgraded shares of Halozyme Therapeutics from a buy rating to a neutral rating and […]